akerotx.com的 10 大竞争对手

gossamerbio.com

USA Office3115 Merryfield RowSuite 120San Diego, CA 92121 Ireland Office77 Sir John Rogerson’s Quay, Block CGrand Canal DocklandsDublin 2, D02 VK60 Sponsorship DisclosureAnnual Grant & Sponsorship Disclosure Global Reports Grant & Sponsorship Disclosure Global Report 2022 (Download)Grant & Sponsorship Disclosure Global Report 2021 (Download)

sutrobio.com

sutro biopharma, inc. is a public biotechnology company headquartered in south san francisco, california focused on clinical stage drug discovery, development and manufacturing company. using its integrated cell-free protein synthesis platform, xpresscf, to create a variety of protein therapeutics for cancer and autoimmune disorders. it focuses to design therapeutics using potent modalities, including cytokine based immune-oncology (i/o) therapeutics, antibody-drug conjugates (adcs) and bispecific antibodies that are directed primarily against clinically validated targets. its product candidates include stro-001 and stro-002. stro-001 is an adc directed against the cancer target cd74, for patients with multiple myeloma and non-hodgkin lymphoma (nhl). stro-002 is an adc directed against folate receptor-alpha (folra), for patients with ovarian and endometrial cancers. stro-001 and stro-002 are designed and optimized for therapeutic index by placing linker-warheads at specific locations within the antibody using its xpresscf platform.

89bio.com

Clinical-stage biopharmaceutical company dedicated to developing and delivering innovative therapies to treat people with liver and cardiometabolic diseases.

roche.com

Wir beantworten die häufig gestellten Fragen der Roche Investoren

novonordisk.com

We strive for equal opportunities for all employees, and we do our utmost to be able to offer a workplace that’s great to be in.

fiercebiotech.com

|

biopharmadive.com

The latest pharma news for biotech and biopharmaceutical professionals

celldex.com

Celldex is developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate.

molecularpartners.com

Molecular Partners develops DARPin therapeutics for cancer and serious diseases through innovative oncology and radiopharmaceutical programs.

faron.com

Faron Pharmaceuticals Oy (2068285-4) Faron Pharmaceuticals Oy ARTICLES OF ASSOCIATION  (unofficial translation of the Finnish original) As approved by the annual general meeting on 21.3.2025  The information above is disclosed in accordance with Rule 26 of the AIM Rules for Companies.